 Connection
Kevin Messacar to Treatment Outcome
This is a "connection" page, showing publications Kevin Messacar has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.133 |
|
|
|
-
Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology. 2019 04 30; 92(18):e2118-e2126.
Score: 0.061
-
Messacar K, Hurst AL, Child J, Campbell K, Palmer C, Hamilton S, Dowell E, Robinson CC, Parker SK, Dominguez SR. Clinical Impact and Provider Acceptability of Real-Time Antimicrobial Stewardship Decision Support for Rapid Diagnostics in Children With Positive Blood Culture Results. J Pediatric Infect Dis Soc. 2017 Sep 01; 6(3):267-274.
Score: 0.056
-
Kane MS, Sonne C, Zhu S, Malhotra A, Van Haren K, Messacar K, Glaser CA. Incidence, Risk Factors and Outcomes Among Children With Acute Flaccid Myelitis: A Population-based Cohort Study in a California Health Network Between 2011 and 2016. Pediatr Infect Dis J. 2019 07; 38(7):667-672.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|